Disclosure Insight Maintains Medium Risk Rating on Hospira

A report from Disclosure Insight reiterates its Medium Risk – Negative Bias rating on Hospira (NYSE: HSP).

The report states, “Concentrated revenue; patent litigation; a new CEO in Mar-11; guidance cuts; acquisition activity; and one-time items support our opinion of a Medium Risk - Negative Bias rating on HSP. The company's 4 largest wholesalers accounted for 40% of 2010 global sales. HSP is a defendant in patent litigation relating to its generic drug docetaxel and a plaintiff in patent litigation relating to Precedex."

HSP closed yesterday at $31.45.